• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Kansas Distric Court rules in favor of Mylan in EpiPen class action

June 24, 2021 By Sean Whooley

legalViatris (NSDQ:VTRS) announced that the U.S. District Court for the District of Kansas ruled in favor of Mylan in an EpiPen class action.

Mylan, which Pfizer combined with its Upjohn business to form Viatris in November 2020, received a favorable ruling in substantial part that dismissed all of the plaintiffs’ claims under the federal RICO statute, including claims asserted against former Mylan CEO Heather Bresch.

According to a news release, the court also dismissed claims alleging that Mylan foreclosed branded competition through rebate arrangements with pharmacy benefit managers.

The lone remaining claim in the class action suit regards a patent settlement between Pfizer and Teva and other alleged actions pertaining to the launch of Teva’s generic epinephrine auto-injector. Mylan said the ruling “was not a decision on the merits of that claim and did not resolve the claim in plaintiffs’ favor.”

Mylan did say that the decision vindicates its attempts to defend itself against claims related to the EpiPen, with another trial scheduled to begin on Sep. 7, 2021.

“The company firmly believes that Mylan’s conduct was lawful and pro-competitive, and that plaintiffs will have great difficulty proving damages resulting from Mylan’s actions,” the company wrote in the release.

In December 2020, the same court granted summary judgment in Mylan’s favor in a different lawsuit brought by Sanofi, rejecting Sanofi’s claims that Mylan engaged in anticompetitive practices to market EpiPen.

Earlier this year in January, however, a federal judge in Minnesota decided that Mylan must face a lawsuit brought forth by drug wholesalers Rochester Drug CoOperative and Dakota Drug, accusing it of paying bribes and kickbacks to pharmacy benefit managers and of conspiring to fix prices on its EpiPen device.

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Legal News, Pharmaceuticals Tagged With: epipen, Mylan, Viatris

IN CASE YOU MISSED IT

  • FDA approves Medtronic’s Onyx Frontier drug-eluting coronary stent
  • Medtronic completes Intersect ENT acquisition
  • Abbott announces availability of Xience Skypoint drug-eluting stent in extended sizes
  • Here’s what’s next for Insulet after the launch of Omnipod 5, CEO change
  • Senseonics beats The Street in Q1 following Eversense E3 launch

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS